BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

JANX

Janux Therapeutics, Inc. NASDAQ Listed Jun 11, 2021
Healthcare ·Biotechnology ·US · januxrx.com
$14.54
After hrs $13.97 -1.45%
Mkt Cap $884.5M
52w Low $12.12 10.4% of range 52w High $35.34
50d MA $14.34 200d MA $19.58
P/E (TTM) -7.8x
EV/EBITDA -7.4x
P/B 0.9x
Debt/Equity 0.0x
ROE -11.9%
P/FCF -10.3x
RSI (14)
ATR (14)
Beta 2.81
50d MA $14.34
200d MA $19.58
Avg Volume 1.1M
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
SIC Code
2834
CIK (SEC)
Phone
858 750 4700
11099 North Torrey Pines Road · San Diego, CA 92037 · US
Data updated apr 25, 2026 4:39pm · Source: massive.com